How Pancreatic Cancer Outwits a Promising RAS Inhibitor and What to Do About It
New research maps how PDAC tumors escape daraxonrasib and reveals rational drug combinations to overcome resistance.
Summary
Pancreatic cancer remains one of the deadliest cancers, partly because it is driven by mutant KRAS — a target long considered undruggable. Daraxonrasib is a new oral inhibitor that attacks multiple RAS variants simultaneously. In a phase 1/2 trial, it showed real promise against previously treated pancreatic adenocarcinoma. But tumors eventually fought back. Researchers analyzed circulating tumor DNA from 44 patients and found that 59% developed new genomic changes in the RAS signaling pathway during treatment. The most common escape route was amplification of mutant KRAS itself, seen in 36% of patients. Other tumors rewired through MAPK, PI3K, or receptor tyrosine kinase pathways. Importantly, none of the tumors acquired secondary KRAS point mutations — a key difference from older, mutation-selective inhibitors. Preclinical experiments confirmed these resistance mechanisms and showed that combining daraxonrasib with DNA damage response agents, RTK inhibitors, or the mutation-selective RAS inhibitor zoldonrasib could prevent or delay resistance.
Detailed Summary
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with a five-year survival rate below 15%. The near-universal presence of oncogenic KRAS mutations makes RAS inhibition an attractive but historically elusive strategy. Daraxonrasib represents a new generation of RAS inhibitors — orally available, capable of targeting multiple oncogenic and wild-type RAS variants simultaneously through a tri-complex mechanism. Early clinical data showed encouraging responses in previously treated, RAS-mutant metastatic PDAC, motivating a confirmatory phase 3 trial (RASolute 302). Understanding how tumors eventually escape this drug is critical for improving outcomes.
Researchers performed targeted sequencing of over 800 genes in paired pre-treatment and end-of-treatment circulating tumor DNA samples from 44 patients enrolled in the phase 1/2 trial. This liquid biopsy approach allowed real-time capture of tumor evolution without requiring repeat tissue biopsies — a practical advantage in a disease where tumors are often hard to access.
The results were striking. Fifty-nine percent of patients developed treatment-emergent genomic alterations in the RAS signaling pathway. Mutant KRAS amplification was the most prevalent mechanism, found in 36% of patients. MAPK pathway alterations appeared in 25%, while RTK and PI3K changes each appeared in 9%. Crucially, no secondary KRAS point mutations were observed — a resistance pattern seen with older G12C-selective inhibitors — suggesting that pan-RAS inhibition closes off that particular escape route while opening others.
Preclinical models corroborated these clinical findings and provided mechanistic insight. MYC amplification and RTK upregulation also emerged as resistance drivers. Importantly, combining daraxonrasib with DNA damage response inhibitors, RTK-targeted agents, or the mutant-selective RAS(ON) G12D inhibitor zoldonrasib prevented resistance emergence in laboratory models.
For clinicians, these findings create a roadmap: liquid biopsy monitoring during treatment can identify resistance mechanisms early, and rational combinations addressing those mechanisms are now being defined. The major caveat is that this analysis is based on 44 patients and abstract-level data only; full publication details, including statistical robustness, are not yet available. Conflict-of-interest considerations are substantial, as most authors are Revolution Medicines employees.
Key Findings
- 59% of PDAC patients on daraxonrasib developed RAS pathway genomic resistance alterations detectable in circulating tumor DNA.
- Mutant KRAS amplification was the dominant resistance mechanism, occurring in 36% of patients.
- No secondary KRAS point mutations emerged — distinct from resistance seen with G12C-selective inhibitors.
- Combining daraxonrasib with DNA damage response agents, RTK inhibitors, or zoldonrasib prevented resistance in preclinical models.
- Liquid biopsy sequencing of 800+ genes enabled real-time tracking of tumor evolution without repeat tissue biopsies.
Methodology
Targeted sequencing of over 800 genes was performed on paired pre-treatment and end-of-treatment circulating tumor DNA samples from 44 patients in a phase 1/2 clinical trial. Preclinical resistance mechanisms were validated and mechanistically established in human and murine PDAC models. Combination therapy strategies were tested in these preclinical systems.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; detailed statistical analyses, patient characteristics, and methodology cannot be fully assessed. The sample size of 44 patients limits the statistical power to precisely estimate resistance mechanism frequencies. The majority of authors are employees of Revolution Medicines, the drug's developer, representing a significant conflict of interest that warrants independent replication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: